Anti-CEA Immunoconjugates Targeting Inaccessible Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compositions and methods for delivering antibodies and immune adjuvants are inadequate for accessing inaccessible tumors, limiting treatment options for cancer patients.
Innovation Solution
Development of immunoconjugates comprising an anti-Carcinoembryonic Antigen (CEA) antibody conjugated to 8-phenyl-2-aminobenzazepine derivatives, which allows for the covalent binding of the antibody to a linker and subsequent attachment of 8-Phe-2-aminobenzazepine moieties, facilitating targeted cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional antibody delivery compositions are used, then the treatment approach is simple, but the ability to access inaccessible tumors is limited
Solution Approach 1:
The patent combines an anti-CEA antibody with a cytotoxic payload (8-phenyl-2-aminobenzazepine derivative) into a single immunoconjugate molecule. This merging allows the antibody to deliver the toxic payload directly to CEA-expressing tumor cells, enabling access to inaccessible tumors while maintaining a manageable composition structure through covalent bonding via a linker.
2Reliability
If immunoconjugates with covalent binding are used, then targeted cancer treatment is enhanced, but the manufacturing process becomes more complex
Solution Approach 1:
The patent employs a linker molecule as an intermediary to facilitate the covalent bonding between the anti-CEA antibody and the 8-phenyl-2-aminobenzazepine derivative. This intermediary approach enables stable conjugation while providing a controlled manufacturing process, balancing targeted treatment effectiveness with manufacturability through standardized conjugation chemistry.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunoconjugates enable effective targeting and treatment of cancer by enhancing the delivery of antibodies to tumors, expanding treatment options and improving therapeutic outcomes.
Implementation Method 1
an anti-CEA antibody covalently attached to a linker which is covalently attached to one or more 8-Phe-2-aminobenzazepine moieties
Data Source
AI summary
The invention provides immunoconjugates of Formula I comprising an anti-CEA antibody linked by conjugation to one or more 8-phenyl-2-aminobenzazepine derivatives. The invention also provides 8-phenyl-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.